Intriguingly, this axis was impaired in diabetic patients and therapeutic injections of recombinant FcsFNDC4 into pre-diabetic mice corrected pre-diabetic hyperglycemia, now providing a rationale for harnessing the FNDC4–GPR116 axis in pre-diabetes therapy. This evidence concerns the gene FNDC4 and diabetes mellitus.